{"id":"https://openalex.org/W4401435948","doi":"https://doi.org/10.1093/bjd/ljae266.081","title":"707 - Contemporary systemic treatment patterns in atopic dermatitis","display_name":"707 - Contemporary systemic treatment patterns in atopic dermatitis","publication_year":2024,"publication_date":"2024-08-01","ids":{"openalex":"https://openalex.org/W4401435948","doi":"https://doi.org/10.1093/bjd/ljae266.081"},"language":"en","primary_location":{"id":"doi:10.1093/bjd/ljae266.081","doi":"https://doi.org/10.1093/bjd/ljae266.081","is_oa":false,"landing_page_url":"https://doi.org/10.1093/bjd/ljae266.081","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016689555","display_name":"Ann P. Quick","orcid":"https://orcid.org/0000-0003-4223-6217","observed_orcids":["https://orcid.org/0000-0003-4223-6217"]},"institutions":[{"id":"https://openalex.org/I4405272729","display_name":"Castle Biosciences, Inc. (United States)","ror":"https://ror.org/04mp5e251","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272729"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann P Quick","raw_affiliation_strings":["Castle Biosciences, Inc. , Friendswood, TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Castle Biosciences, Inc. , Friendswood, TX , USA","institution_ids":["https://openalex.org/I4405272729"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059790021","display_name":"Lenka V. Hurton","orcid":"https://orcid.org/0000-0001-5670-5155","observed_orcids":["https://orcid.org/0000-0001-5670-5155"]},"institutions":[{"id":"https://openalex.org/I4405272729","display_name":"Castle Biosciences, Inc. (United States)","ror":"https://ror.org/04mp5e251","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272729"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lenka V Hurton","raw_affiliation_strings":["Castle Biosciences, Inc. , Friendswood, TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Castle Biosciences, Inc. , Friendswood, TX , USA","institution_ids":["https://openalex.org/I4405272729"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079584255","display_name":"Olga Zolochevska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272729","display_name":"Castle Biosciences, Inc. (United States)","ror":"https://ror.org/04mp5e251","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272729"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olga Zolochevska","raw_affiliation_strings":["Castle Biosciences, Inc. , Friendswood, TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Castle Biosciences, Inc. , Friendswood, TX , USA","institution_ids":["https://openalex.org/I4405272729"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002940170","display_name":"Aaron S. Farberg","orcid":"https://orcid.org/0000-0001-9572-8683","observed_orcids":["https://orcid.org/0000-0001-9572-8683"]},"institutions":[{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron S Farberg","raw_affiliation_strings":["Bare Dermatology , Dallas, TX , USA","Baylor Scott & White Health System , Dallas, TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bare Dermatology , Dallas, TX , USA","institution_ids":[]},{"raw_affiliation_string":"Baylor Scott & White Health System , Dallas, TX , USA","institution_ids":["https://openalex.org/I4210160418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031633287","display_name":"Matthew S. Goldberg","orcid":"https://orcid.org/0000-0002-5186-6491","observed_orcids":["https://orcid.org/0000-0002-5186-6491"]},"institutions":[{"id":"https://openalex.org/I4405272729","display_name":"Castle Biosciences, Inc. (United States)","ror":"https://ror.org/04mp5e251","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272729"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S Goldberg","raw_affiliation_strings":["Castle Biosciences, Inc. , Friendswood, TX , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Castle Biosciences, Inc. , Friendswood, TX , USA","institution_ids":["https://openalex.org/I4405272729"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011739266","display_name":"Jonathan I. Silverberg","orcid":"https://orcid.org/0000-0003-3686-7805","observed_orcids":["https://orcid.org/0000-0003-3686-7805"]},"institutions":[{"id":"https://openalex.org/I193531525","display_name":"George Washington University","ror":"https://ror.org/00y4zzh67","country_code":"US","type":"education","lineage":["https://openalex.org/I193531525"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan I Silverberg","raw_affiliation_strings":["Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC , USA","institution_ids":["https://openalex.org/I193531525"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3918,"currency":"GBP","value_usd":5008},"apc_paid":null,"fwci":1.3692,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.814544,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":98},"biblio":{"volume":"191","issue":"Supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atopic-dermatitis","display_name":"atopic dermatitis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/targeted-biologic-therapy","display_name":"targeted biologic therapy","score":0.656000018119812},{"id":"https://openalex.org/keywords/dupilumab","display_name":"dupilumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/upadacitinib","display_name":"upadacitinib","score":0.9490000009536743},{"id":"https://openalex.org/keywords/tralokinumab","display_name":"tralokinumab","score":0.9160000085830688},{"id":"https://openalex.org/keywords/abrocitinib","display_name":"abrocitinib","score":1.0},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.7649999856948853},{"id":"https://openalex.org/keywords/il-13-inhibition","display_name":"IL-13 inhibition","score":0.828000009059906},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.8629999756813049},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/real-world-prescribing","display_name":"real-world prescribing","score":0.5820000171661377},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.6759999990463257},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.3449999988079071},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.3149999976158142},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8796278238296509},{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.8475044369697571},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.7692039012908936},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.5535375475883484},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.5406894087791443},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5068290829658508},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.4875602126121521},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48035988211631775},{"id":"https://openalex.org/C2780699399","wikidata":"https://www.wikidata.org/wiki/Q20708049","display_name":"Eczema Area and Severity Index","level":3,"score":0.4408813416957855},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4304673969745636},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.2688358724117279},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.10209828615188599},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.0},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/bjd/ljae266.081","doi":"https://doi.org/10.1093/bjd/ljae266.081","is_oa":false,"landing_page_url":"https://doi.org/10.1093/bjd/ljae266.081","pdf_url":null,"source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.7099999785423279,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4287189041","https://openalex.org/W3167826726","https://openalex.org/W3185091247","https://openalex.org/W3180031743","https://openalex.org/W4390918003","https://openalex.org/W4237621822","https://openalex.org/W3204561650","https://openalex.org/W3009721489","https://openalex.org/W2766528424","https://openalex.org/W3029347445"],"abstract_inverted_index":{"Abstract":[0],"Introduction/Background":[1],"With":[2],"newly":[3],"emerging":[4,598],"targeted":[5,40,92,142,205,248,252,331,349,398,471],"systemic":[6,103,143,172,206,253,332,360,399],"therapies":[7,41,207,229,527,586],"for":[8,34,57,95,155,188,208,241,540,555,580,601],"atopic":[9],"dermatitis":[10,444],"(AD)":[11],"there":[12,535],"is":[13,97],"a":[14,140,147,183,231,307,330,467,478,578],"need":[15,579],"to":[16,177,250,269,275,278,282,289,296,306,314,347,357,369,446,470,545,587],"understand":[17],"the":[18,29,43,75,236,263,338,552,594,597],"evolving":[19],"real-world":[20,90,112],"treatment":[21,67,93,104,173,234,410,554,599],"patterns":[22,105],"and":[23,47,52,119,165,179,197,217,259,280,313,316,321,343,442,485,501,516],"implications":[24],"on":[25,89,225,378,408,568],"AD":[26,61,96,131,144,171,350,547],"management.":[27],"Since":[28],"FDA":[30,72],"approval":[31],"of":[32,63,116,159,185,222,227,244,246,284,384,392,420,431,477,481,492,531,551,558,573,585,596],"dupilumab":[33,211,266,409],"adults":[35,58,209],"in":[36,106,135,233,460,593],"2017,":[37],"three":[38],"additional":[39],"\u2013":[42,54],"IL-13":[44],"inhibitor":[45,77],"tralokinumab":[46,215,277],"2":[48],"JAK":[49],"inhibitors":[50],"(abrocitinib":[51],"upadacitinib)":[53],"were":[55,133,180,200,255],"approved":[56],"with":[59,108,129,146,303,329,528,542],"moderate-to-severe":[60],"as":[62,436,487],"January":[64,163],"2022.":[65],"Additional":[66],"options":[68,539],"are":[69,533],"still":[70],"awaiting":[71],"approval,":[73],"including":[74],"IL-31":[76],"nemolizumab,":[78],"or":[79,363,456,508,561],"undergoing":[80],"clinical":[81],"trials":[82],"(e.g.,":[83],"OX40-OX40L":[84],"inhibitors).":[85],"Therefore,":[86],"an":[87,130,453],"update":[88],"contemporary":[91],"strategies":[94,592],"warranted.":[98],"Objectives":[99],"To":[100],"characterize":[101],"current":[102],"patients":[107,223,304,326,353,375,462,493,541,559,565],"AD.":[109,602],"Methods":[110],"A":[111],"retrospective":[113],"observational":[114],"analysis":[115,136],"US":[117],"medical":[118],"prescription":[120,145],"claims":[121],"data":[122],"(IQVIA,":[123],"Durham,":[124],"NC)":[125],"was":[126,475],"assessed.":[127],"Individuals":[128],"diagnosis":[132,455],"included":[134,210],"if":[137],"they":[138],"initiated":[139],"modern":[141],"dermatology":[148],"provider":[149],"at":[150,300,310,319],"index":[151,178,553,569],"(patient":[152],"selection":[153,584],"event)":[154],"their":[156,379,396],"first":[157,380,397],"line":[158,204],"therapy":[160,254],"(LOT)":[161],"between":[162],"2022":[164],"June":[166],"2023,":[167],"but":[168],"had":[169,382,416,571],"no":[170],"24":[174],"months":[175,187,312,342],"prior":[176],"continuously":[181],"enrolled":[182],"minimum":[184],"six":[186],"follow-up":[189,237],"(n=7006).":[190],"Treatment":[191],"patterns,":[192],"switch":[193,346],"rates,":[194,302],"comedications,":[195],"comorbidities,":[196],"post-index":[198,421],"events":[199],"evaluated.":[201],"Results":[202],"First":[203],"(91.2%),":[212],"upadacitinib":[213,272],"(4.3%),":[214],"(3.9%),":[216],"abrocitinib":[218,281],"(0.7%).":[219],"Fifty-one":[220],"percent":[221],"initiating":[224],"one":[226,335],"these":[228,247],"underwent":[230],"change":[232],"during":[235],"period.":[238],"Switch":[239],"rates":[240,419,430],"monotherapy":[242,267],"use":[243,273],"each":[245],"drugs":[249],"another":[251,348],"5%,":[256],"10%,":[257],"18%,":[258],"17%,":[260],"respectively.":[261,324],"For":[262,388],"second":[264],"LOT,":[265],"decreased":[268],"11%":[270],"whereas":[271],"increased":[274,429,490],"42%,":[276],"25%,":[279,514],"8%":[283],"LOT-2.":[285],"On":[286],"average,":[287],"switches":[288],"LOT-2":[290],"occurred":[291,299],"within":[292,340],"5.5":[293],"months.":[294],"Switches":[295],"later":[297],"LOTs":[298,318],"quicker":[301],"switching":[305],"third":[308,336],"LOT":[309,381,400],"4.6":[311],"4th":[315],"5th":[317],"3.1":[320],"3.3":[322],"months,":[323],"Of":[325],"only":[327],"treated":[328],"LOT-1,":[333],"over":[334,390,582],"discontinued":[337,560],"drug":[339],"\u223c5":[341],"did":[344,449,464],"not":[345,465],"therapy.":[351,548],"These":[352],"may":[354],"have":[355],"switched":[356,372,562],"other":[358,432],"non-targeted":[359],"treatments,":[361],"topicals,":[362],"ceased":[364],"any":[365],"treatment.":[366,472],"In":[367],"addition":[368],"those":[370,447],"who":[371,376,394,406,448,463,566],"therapies,":[373],"some":[374,461],"remained":[377,567],"evidence":[383],"persisting":[385],"disease":[386,483,575],"burden.":[387],"instance,":[389],"half":[391],"individuals":[393],"maintained":[395],"also":[401],"used":[402],"topical":[403,495],"therapies.":[404,563],"Those":[405],"persisted":[407],"despite":[411],"continuing":[412],"pruritus":[413,474],"(641/6001,":[414],"11%)":[415],"2.6x":[417],"higher":[418,479],"biopsy":[422],"(5%":[423],"vs":[424,498,505,513,520],"14%,":[425],"p<.001)":[426,500,515,522],"accompanied":[427],"by":[428,489],"cutaneous":[433],"diagnoses":[434],"such":[435],"mycosis":[437],"fungoides,":[438],"contact":[439],"dermatitis,":[440],"tinea,":[441],"seborrheic":[443],"compared":[445],"not.":[450],"This":[451],"suggests":[452],"unclear":[454],"multiple":[457],"pruritic":[458],"conditions":[459],"achieve":[466],"robust":[468],"response":[469,544],"Post-index":[473],"suggestive":[476],"level":[480],"overall":[482],"burden":[484],"comorbidities":[486],"observed":[488],"proportions":[491],"using":[494],"corticosteroids":[496],"(61%":[497],"50%,":[499],"antianxiety":[502],"medications":[503],"(33%":[504],"20%,":[506],"p<.001),":[507],"seeing":[509],"emergency":[510],"medicine":[511],"(35%":[512],"cardiovascular":[517],"specialists":[518],"(25.9%":[519],"17.2%,":[521],"post":[523],"index.":[524],"As":[525],"new":[526],"different":[529],"mechanisms":[530],"action":[532],"approved,":[534],"will":[536],"be":[537],"more":[538,589],"incomplete":[543],"first-line":[546],"Conclusions":[549],"Irrespective":[550],"AD,":[556],">50%":[557],"Some":[564],"treatment,":[570],"indicators":[572],"inadequate":[574],"control,":[576],"suggesting":[577],"improvement":[581],"empirical":[583],"support":[588],"proactive":[590],"management":[591],"context":[595],"landscape":[600]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2025-10-10T00:00:00"}